Latest Content
-
Learn MoreHow the UK's HTA Agency Uses Real-World Evidence to Develop Guidance
The UK national health technology assessment (HTA) body, the National Institute for Health and Clinical Excellence (NICE), made a long-awaited announcement last week: NICE has expanded the...
-
2:06Watch VideoRare Diseases: Aligning Expertise
See how Parexel are bringing together regulatory and market access experts to help companies developing rare and orphan disease products. Learn more about our Regulatory & Access Consulting Group: htt
-
Learn MoreEpisode 4: Accelerated Regulatory Pathways and Patient Access
In this episode, Parexel’s Mwango Kashoki, a former FDA regulator, and Richard Macaulay, who specializes in market access challenges, join Alberto Grignolo to discuss expedited regulatory pathways...
-
Learn MoreBeware of Regional Donor Eligibility Requirements: They're Not Really the Same Everywhere!
Donor Eligibility (DE) determination is a central aspect of how FDA and other regulatory authorities ensure that a product from a single allogeneic donor has acceptable very low risk of...
-
Learn MoreFDA Inspections and Cleaning
Companies often have many questions concerning their approach to cleaning validation when it comes to preparing for an FDA Inspection. Often cleaning validation studies are extensively...
-
Learn MoreCan FDA Really Do That? Understanding FDA’s Jurisdiction
On August 29, 2019 the US FDA sent a Warning Letter to Shanghai Institute of Pharmaceutical Industry (SIPI) (see the Warning Letter). The FDA charged the firm with refusing a pre-announced...
-
Learn MoreRare Disease and Orphan Drug Designations - What You Need to Know
Collectively, rare diseases affect over 30 million Americans. The Orphan Drug Act (ODA), which provides the statutory basis for FDA to designate a drug or biologic agent as a therapy for a...
-
Learn MoreCritical Differences Between a Form FDA 483 and Warning Letters
There are many publications and services that analyze the observations contained in Form FDA 483 documents issued to manufacturers at the close of an inspection by the U.S. Food and Drug...
-
Learn MoreDoes FDA Consistently Assess Product Quality Risk and Control in Applications?
Early in 2018, the Food and Drug Administration’s (FDA) Office of Pharmaceutical Quality (OPQ) published a “white paper” which contained recommendations that drug companies could consider...
-
Learn MorePress announcement: Parexel unveils combined Regulatory & Access consulting organization
-
Learn MoreReimagining The Global Value Dossier - Part 6
A clear value strategy is key to the success of any product attempting to enter the healthcare market; defining the right strategy should lead to the perfect positioning for your product and...
-
Learn MoreDon’t Shortchange Your Due Diligence When It Involves Applications – FDA Won’t
In a recent blog post, I wrote about how manufacturers can overcome data integrity problems that potentially imperil an application’s approval and commercializing a product. Sometimes...
-
Learn MoreHow to align your market access activities with your product value strategy
The value strategy (also termed value story) for your product should act as the cornerstone for all market access activities. The value strategy drives your market access planning, which...
-
Learn MoreDemystifying FDA’s KASA Initiative… and how it aims to improve drug product, facility, and corporate quality monitoring
What is KASA and why does FDA need it? Due to issues stemming from the large volume of generic drug applications submitted to the agency and the fact that some of the submissions are have...
-
Learn MoreBiosimilars in China: Riding an upward trend
In February 2019, National Drug Regulators in China approved the country’s first ever biosimilar product referencing Rituxan, a monoclonal antibody[1]. This biosimilar product, HLX01...
-
Learn MoreRescuing Product Approvals from Data Integrity Issues
The pharmaceutical industry is inundated with a plethora of communications about data integrity. Most of those are focused on the downside – operational snags, negative inspection findings,...
-
Learn MoreReimagining the Global Value Dossier - Part 4
Health Technology Assessment (HTA) agencies are increasingly demanding the inclusion of patient-relevant data in submission dossiers. It is evident that there is an effort to ensure...
-
Learn MoreCommercializing Gene and Cellular Therapy
Gene and cellular therapy manufacturing requires strict control in current Good Manufacturing Practice (cGMP) facilities. Designing a facility or finding a contract manufacturer to meet the...
-
Learn MoreCapturing the patient voice in market access communications
Patients have unique perspectives on their conditions that, when incorporated into value communications, can provide an authenticity and salience which would otherwise be lacking. Who knows...
-
Learn MoreLandscape assessment and key HTA considerations in Alzheimer’s disease
-
Loading More...
